Nab-rapamyci (** Currently investigational - no approved brand names available. The compound is also known as ABI-009. **)
Investigational
Description
Nab-rapamycin (also known as ABI-009) is an investigational drug currently being studied in clinical trials for various advanced cancers, including certain types of colorectal cancer. It is being tested in combination with another investigational drug called nivolumab. In the context of colorectal cancer, nab-rapamycin is being studied specifically in patients whose tumors are MSI-H (microsatellite instability-high) or dMMR (mismatch repair deficient). These are specific characteristics of some colorectal cancers. The goal of the trials is to determine the right dose of nab-rapamycin and to see how effective the combination of nab-rapamycin and nivolumab is in treating these cancers. It is important to note that nab-rapamycin is not yet approved for use in colorectal cancer or any other cancer.
Mechanism of Action
Nab-rapamycin is classified as an mTOR inhibitor. mTOR (mammalian target of rapamycin) is a protein that plays a key role in cell growth, division, and survival. By inhibiting mTOR, nab-rapamycin aims to block signals that promote cancer cell growth and proliferation. The specific way nab-rapamycin interacts with mTOR and its precise effects on cancer cells are being further investigated in clinical trials.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.